Additional safety risk to exceptionally approved drugs in Europe?

被引:34
作者
Arnardottir, Arna H. [1 ]
Haaijer-Ruskamp, Flora M. [1 ]
Straus, Sabine M. J. [2 ,3 ]
Eichler, Hans-Georg [4 ]
de Graeff, Pieter A. [1 ,2 ]
Mol, Peter G. M. [1 ,2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, NL-9700 AD Groningen, Netherlands
[2] Dutch Med Evaluat Board CBG MEB, The Hague, Netherlands
[3] Erasmus MC, Rotterdam, Netherlands
[4] European Med Agcy, London, England
关键词
conditional approval; drug safety; exceptional circumstances; licensing of drugs; regulatory affairs; REGULATORY ACTIONS; HEALTH-CARE; NETHERLANDS; INNOVATION; BENEFIT; ACCESS;
D O I
10.1111/j.1365-2125.2011.03995.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIMS Regulatory requirements for new drugs have increased. Special approval procedures with priority assessment are possible for drugs with clear 'unmet medical need'. We question whether these Exceptional Circumstances (EC) or Conditional Approval (CA) procedures have led to a higher probability of serious safety issues. METHODS A retrospective cohort study was performed of new drugs approved in Europe between 1999 and 2009. The determinant was EC/CA vs. standard procedure approval. Outcome variables were frequency and timing of a first Direct Healthcare Professional Communication (DHPC). An association between approval procedure and the time from market approval to DHPC was assessed using Kaplan-Meyer survival analysis and Cox-regression to correct for covariates. RESULTS In total 289 new drugs were approved. Forty-six (16.4%) were approved under EC or CA, of which seven received a DHPC (15%). This was similar to the standard approval drugs (243), of which 33 received one or more DHPC (14%, P = 0.77). The probability of acquiring a DHPC for standard approval drugs vs. EC/CA drugs during 11-year follow-up is 22% (95% CI 14%, 29%) and 26% (95% CI 8%, 44%), respectively (log-rank P = 0.726). This difference remained not significant in the Cox-regression model: hazard ratio 0.94 (95% CI 0.40, 2.20). Only drug type was identified as a confounding covariate. CONCLUSION The EC/CA procedure is not associated with a higher probability of DHPCs despite limited clinical development data. These data do not support the view that early drug approval increases the risk of serious safety issues emerging after market approval.
引用
收藏
页码:490 / 499
页数:10
相关论文
共 27 条
[1]  
[Anonymous], RUL GOV MED PROD E A
[2]  
[Anonymous], 1999, REP FDA COMM MAN RIS
[3]  
[Anonymous], 2005, INT C HARM TECHN REQ
[4]  
[Anonymous], ATC/DDD Index 2019
[5]   Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe [J].
Boon, W. P. C. ;
Moors, E. H. M. ;
Meijer, A. ;
Schellekens, H. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) :848-853
[6]   Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics [J].
Califf, Robert M. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (01) :5-16
[7]   Drug-review deadlines and safety problems [J].
Carpenter, Daniel ;
Zucker, Evan James ;
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13) :1354-1361
[8]   Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline [J].
Darpo, B ;
Nebout, T ;
T Sager, P .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (05) :498-507
[9]   Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma [J].
Eichler, Hans-Georg ;
Pignatti, Francesco ;
Flamion, Bruno ;
Leufkens, Hubert ;
Breckenridge, Alasdair .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (10) :818-826
[10]   New drug approval success rate in Europe in 2009 [J].
Eichler, Hans-Georg ;
Aronsson, Bo ;
Abadie, Eric ;
Salmonson, Tomas .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (05) :355-356